Compulsory Licensing of Patents: Balancing Innovation and Public Access in the Philippines

The Philippine Supreme Court's 1997 decision in Smith Kline & French Laboratories, Ltd. v. Court of Appeals (G.R. No. 121867) remains a cornerstone of Philippine intellectual property law. It affirmed the government's power to grant compulsory licenses over patented medicines—a mechanism that balances a patent holder's exclusive rights against the public's need for accessible healthcare. For businesses and innovators, understanding this ruling is essential to navigating the intersection of patent protection and public welfare.

The Case: A Foreign Patent Holder vs. A Local Drug Manufacturer

Smith Kline & French Laboratories, a British pharmaceutical company, owned Philippine Letters Patent No. 12207 for Cimetidine, a drug used to treat ulcers. In 1987, Doctors Pharmaceuticals, Inc., a domestic manufacturer, petitioned the Bureau of Patents, Trademarks and Technology Transfer (BPTTT) for a compulsory license to produce its own brand of medicine containing Cimetidine.

Doctors Pharmaceuticals filed its petition under Section 34 of Republic Act No. 165, the Philippine Patent Law, which allows compulsory licensing of patents relating to food, medicine, or substances necessary for public health. The petition came more than two years after the patent's grant in 1978, satisfying the law's waiting period.

Smith Kline opposed the petition, arguing that Doctors Pharmaceuticals lacked the capability to work the patent, that the company was merely motivated by profit, and that the compulsory licensing provisions of R.A. No. 165 were unconstitutional. The BPTTT granted the license anyway, imposing a 2.5% royalty rate on net sales. The Court of Appeals affirmed, and Smith Kline appealed to the Supreme Court.

The Legal Issue: Can the State Compel a Patent License?

The central question was whether the compulsory licensing provisions of R.A. No. 165—specifically Section 34, which allows licenses for patents on medicines—were valid under Philippine law and consistent with international treaty obligations.

Smith Kline raised several arguments: that the grant violated the Paris Convention for the Protection of Industrial Property, that it was an invalid exercise of police power, that the royalty rate amounted to expropriation without just compensation, and that the BPTTT lacked jurisdiction due to procedural defects.

The Ruling: Compulsory Licensing Is a Valid Exercise of State Power

The Supreme Court denied the petition and affirmed the compulsory license in full. The Court held that:

1. The Paris Convention permits compulsory licensing. Article 5 of the Paris Convention expressly allows member countries to adopt legislative measures granting compulsory licenses to prevent abuses from the exercise of exclusive patent rights. The Court noted that preventing monopolies was precisely the kind of abuse the Convention contemplated. The two-year waiting period in Philippine law was consistent with the treaty's requirements.

2. The GATT treaty did not apply retroactively. The Uruguay Round agreements, which the Philippines signed in 1994, could not affect the BPTTT's 1994 decision because treaties generally have no retroactive effect.

3. Compulsory licensing is a valid exercise of police power. The State may regulate private rights to promote public health. The Court cited its earlier ruling in Parke, Davis & Co. v. Doctors' Pharmaceuticals, Inc., which held that a patent holder is not unduly deprived of property rights when the law grants a period of exclusive monopoly followed by compulsory licensing with reasonable royalties.

4. The royalty rate was just compensation. The law caps royalties at 5% of net wholesale price. The BPTTT's 2.5% rate was within its sound discretion and was consistent with prior cases, including Price v. United Laboratories, which found a similar rate just and reasonable.

5. Procedural objections came too late. Smith Kline raised the jurisdiction issue only on appeal, and the Court barred the challenge on grounds of laches and estoppel.

The Statutory Framework: Section 34 of R.A. No. 165

The decision anchored on Section 34 of R.A. No. 165, which permits compulsory licensing after two years from a patent's grant under several circumstances, including:

• The patented invention is not being worked in the Philippines on a commercial scale;
• The demand for the patented article is not being met adequately and on reasonable terms;
• The patentee's refusal to grant licenses on reasonable terms prevents new trade or industry;
• Importation prevents or hinders the working of the invention; or
• The patented invention relates to food, medicine, or substances necessary for public health or public safety.

The law requires the applicant to prove its capability to work the patent. Notably, importation does not constitute "working" a patent—a rule that protects local manufacturing.

Practical Takeaways

• Patent rights are not absolute. Philippine law conditions exclusive rights on public welfare, particularly for medicines and food products essential to public health.
• Compulsory licensing requires proof of capability. An applicant must demonstrate it can actually manufacture or use the patented invention, not merely speculate about doing so.
• Royalties must be reasonable. The law caps royalties at 5% of net wholesale price, and the patent office has discretion to fix a lower rate based on the circumstances.
• Treaty compliance matters. The Philippines' obligations under the Paris Convention expressly accommodate compulsory licensing, so international law does not shield patent holders from such grants.
• Procedural objections must be raised early. Challenges to an agency's jurisdiction should be raised promptly, or they may be barred by laches.

This article is general information and not legal advice. For your specific situation, consult a lawyer or ask ASG Legal AI.